Indications for TROGARZO:
In combination with other antiretroviral(s) for HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
Give as IV infusion over ≥30mins for 1st infusion; may reduce to ≥15mins for subsequent infusions if no infusion-associated adverse reactions have occurred. 2000mg as single loading dose followed by 800mg maintenance dose every 2 weeks. Observe patient for 1hr after completing the 1st infusion.
Discontinue immediately if hypersensitivity reactions (including infusion-related or anaphylactic reactions) occur; treat appropriately. Immune reconstitution inflammatory syndrome (in combination with other antiretrovirals). Embryo-fetal toxicity. Pregnancy: may affect immune responses in infants exposed in utero; monitor for reversible immunosuppression; do immune phenotyping and consult expert. Nursing mothers: not recommended.
CD4-directed post-attachment HIV-1 inhibitor.
Diarrhea, dizziness, nausea, rash; lab abnormalities.
To register pregnant patients to the Antiretroviral Pregnancy Registry, call (800) 258–4263.
Generic Drug Availability:
Single-dose vials (2mL)—2